riluzole has been researched along with Affective Psychosis, Bipolar in 6 studies
Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This was an 8-week add-on study of riluzole in combination with lithium in acutely depressed bipolar patients aged 18 years and older." | 2.71 | An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. ( Charney, DS; De Jesus, G; Denicoff, KD; Luckenbaugh, DA; Manji, HK; Quiroz, JA; Singh, JB; Zarate, CA, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (66.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Park, LT | 1 |
| Lener, MS | 1 |
| Hopkins, M | 1 |
| Iadorola, N | 1 |
| Machado-Vieira, R | 1 |
| Ballard, E | 1 |
| Nugent, A | 1 |
| Zarate, CA | 4 |
| Salvadore, G | 1 |
| Drevets, WC | 1 |
| Henter, ID | 1 |
| Manji, HK | 2 |
| Brennan, BP | 1 |
| Hudson, JI | 1 |
| Jensen, JE | 1 |
| McCarthy, J | 1 |
| Roberts, JL | 1 |
| Prescot, AP | 1 |
| Cohen, BM | 1 |
| Pope, HG | 1 |
| Renshaw, PF | 1 |
| Ongür, D | 1 |
| Singh, J | 1 |
| Krystal, AD | 1 |
| Quiroz, JA | 1 |
| Singh, JB | 1 |
| Denicoff, KD | 1 |
| De Jesus, G | 1 |
| Luckenbaugh, DA | 1 |
| Charney, DS | 1 |
| Kugaya, A | 1 |
| Sanacora, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Investigation of the Antidepressant Efficacy of an Antiglutamatergic Agent in Bipolar Depression[NCT00054704] | Phase 2 | 19 participants (Actual) | Interventional | 2003-02-28 | Terminated (stopped due to Placebo was better than active drug.) | ||
| Riluzole in the Treatment of Bipolar Depression: A Study of the Association Between Clinical Response and Change in Brain Glutamate Levels as Measured by Proton Magnetic Resonance Spectroscopy[NCT00544544] | 14 participants (Actual) | Interventional | 2007-06-30 | Completed | |||
| Imaging Framework for Testing GABAergic/Glutamatergic Drugs in Bipolar Alcoholics[NCT03220776] | Phase 2 | 54 participants (Actual) | Interventional | 2017-08-07 | Completed | ||
| An Investigation of the Efficacy in Childhood Obsessive-Compulsive Disorder of Riluzole: An Antiglutamatergic Agent[NCT00251303] | Phase 2 | 78 participants (Actual) | Interventional | 2005-08-31 | Completed | ||
| A Double-Blind Placebo Controlled Trial of Riluzole in Bipolar Depression[NCT00376220] | Phase 2 | 94 participants (Actual) | Interventional | 2004-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Montgomery-Asberg Depression Rating Scale (MADRS) is a clinician-rated assessment of depression symptoms. Patients were rated weekly on 10 symptoms on a scale of 0 to 6 for each item, where 0 indicated no symptoms and 6 indicated the highest severity of that symptom. Total scores range from 0 to 60, where a moderate severity of depression would be present with a score of at least 20. (NCT00054704)
Timeframe: 8 weeks
| Intervention | Units on a scale (Least Squares Mean) |
|---|---|
| Riluzole | 29.551 |
| Placebo | 23.723 |
The Hamilton Depression rating Scale is a clinician-rated scale that measures the severity of depression symptoms using 21 items. Minimum score is zero and maximum score is 65. Higher scores indicate more severe depressive symptoms. (NCT00544544)
Timeframe: Baseline (week 0) - week 6
| Intervention | units on a scale (Mean) |
|---|---|
| Riluzole | -12.6 |
The Clinical Global Impression Scale is a clinician-rated scale that evaluates the severity of illness at the time of assessment. The score ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). (NCT00544544)
Timeframe: Baseline (week 0) - week 6
| Intervention | units on a scale (Mean) |
|---|---|
| Riluzole | -1.6 |
The Montgomery-Asberg Depression Rating Scale is a clinician-rated scale that measures the severity of depression symptoms. The 10 items measured are apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Minimum score is zero and maximum score is 60. Higher scores represent more severe depressive symptoms. (NCT00544544)
Timeframe: Baseline (week 0) - week 6
| Intervention | units on a scale (Mean) |
|---|---|
| Riluzole | -13.0 |
The Young Mania Rating Scale is a clinician-rated scale that measures the severity of mania symptoms. The 11 items measures are elevated mood, increased motor activity, sexual interest, sleep, irritability, speech, language-thought disorder, thought content, aggressive behavior, appearance, and insight. Minimum score is zero and maximum score is 60. Higher scores represent more severe mania symptoms. (NCT00544544)
Timeframe: Baseline (week 0) - week 6
| Intervention | units on a scale (Mean) |
|---|---|
| Riluzole | -0.6 |
Concentrations of GABA+, referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy (i.e., MEGA-PRESS). (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 3.90 |
| Gabapentin | 3.93 |
| Placebo Oral Tablet | 3.73 |
Concentrations of Glx (i.e., glutamate + glutamine), referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy. (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 21.59 |
| Gabapentin | 21.69 |
| Placebo Oral Tablet | 22.25 |
CY-BOCS is a 0-40 point scale of obsessive-compulsive symptom severity, higher number indicates more severe obsessive-compulsive symptoms. Comparison of 12 weeks scores for placebo and riluzole groups. (NCT00251303)
Timeframe: 12 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Riluzole | 21.72 |
| Placebo | 23.30 |
(NCT00251303)
Timeframe: 12 weeks
| Intervention | participants (Number) |
|---|---|
| Riluzole | 3 |
| Placebo | 4 |
The Montgomery Asberg Depression Rating Scale measures symptoms of depression (MADRS) is a semi-structured interview rating scale for depression that assesses 10 symptoms. The scale is composed of 10 questions with a fixed 7 point scale (0-6). Total score ranges from 0-60. A higher score indicates more depressive symptoms. MADRS Response will be defined as a > 50% reduction in MADRS score from baseline. (NCT00376220)
Timeframe: 8 weeks
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline MADRS | Week 8 | |
| Active Treatment Group | 32.4 | 21.7 |
| Inactive/Placebo Group | 30.4 | 19.0 |
2 reviews available for riluzole and Affective Psychosis, Bipolar
| Article | Year |
|---|---|
Early intervention in bipolar disorder, part II: therapeutics.
Topics: Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Brain; Early Diagnosis; Humans; Lamotrigin | 2008 |
Beyond monoamines: glutamatergic function in mood disorders.
Topics: Bipolar Disorder; Brain; Clinical Trials as Topic; Depressive Disorder, Major; Excitatory Amino Acid | 2005 |
2 trials available for riluzole and Affective Psychosis, Bipolar
| Article | Year |
|---|---|
A Double-Blind, Placebo-Controlled, Pilot Study of Riluzole Monotherapy for Acute Bipolar Depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Double-Blind Method; Excitatory Amino Acid Antagonists; H | 2017 |
An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Drug Therapy, Combination; Excitatory Amino Acid Antagoni | 2005 |
An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Drug Therapy, Combination; Excitatory Amino Acid Antagoni | 2005 |
An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Drug Therapy, Combination; Excitatory Amino Acid Antagoni | 2005 |
An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Drug Therapy, Combination; Excitatory Amino Acid Antagoni | 2005 |
2 other studies available for riluzole and Affective Psychosis, Bipolar
| Article | Year |
|---|---|
Rapid enhancement of glutamatergic neurotransmission in bipolar depression following treatment with riluzole.
Topics: Adult; Bipolar Disorder; Female; Glutamic Acid; Gyrus Cinguli; Humans; Male; Middle Aged; Psychiatri | 2010 |
Rapid enhancement of glutamatergic neurotransmission in bipolar depression following treatment with riluzole.
Topics: Adult; Bipolar Disorder; Female; Glutamic Acid; Gyrus Cinguli; Humans; Male; Middle Aged; Psychiatri | 2010 |
Rapid enhancement of glutamatergic neurotransmission in bipolar depression following treatment with riluzole.
Topics: Adult; Bipolar Disorder; Female; Glutamic Acid; Gyrus Cinguli; Humans; Male; Middle Aged; Psychiatri | 2010 |
Rapid enhancement of glutamatergic neurotransmission in bipolar depression following treatment with riluzole.
Topics: Adult; Bipolar Disorder; Female; Glutamic Acid; Gyrus Cinguli; Humans; Male; Middle Aged; Psychiatri | 2010 |
Case report: Successful riluzole augmentation therapy in treatment-resistant bipolar depression following the development of rash with lamotrigine.
Topics: Adult; Antidepressive Agents; Bipolar Disorder; Drug Synergism; Exanthema; Excitatory Amino Acid Ant | 2004 |